Comparing tolerability of olanzapine in schizophrenia and affective disorders: A meta-analysis

Pharmacology, Toxicology and Pharmaceutical Science

• Tolerability 100%
• Mood Disorder 100%
• Olanzapine 100%
• Adverse Event 75%
• Bipolar Disorder 58%
• Triacylglycerol 33%
• Parkinsonism 25%
• Extrapyramidal Symptoms 25%
• Cardiovascular Disease 16%
• Monotherapy 16%
• Akathisia 16%
• Disease 8%
• Non Insulin Dependent Diabetes Mellitus 8%
• Low Density Lipoprotein 8%
• Metabolic Syndrome X 8%
• Randomized Clinical Trial 8%
• Randomized Controlled Trial 8%
• Major Depression 8%
• Antiparkinson Agent 8%
• Antipsychotic 8%
• Tardive Dyskinesia 8%
• Bipolar Mania 8%
• Bipolar Depression 8%

Keyphrases

• Exercise Stress 10%
• Metabolic Issue 10%
• Antiparkinsonian Drugs 10%
• Genetic Disposition 10%
• Olanzapine-induced Weight Gain 10%
• Expanded Indication 10%
• Olanzapine Monotherapy 10%
• Age Ratio 10%
• Industry Sponsorship 10%